Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

被引：72

作者：

Atreya, Raja

Neurath, Markus F.

机构：

[1] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany

[2] Univ Erlangen Nurnberg, Ludwig Demling Endoscopy Ctr Excellence, Erlangen, Germany

来源：

LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 11期

关键词：

TUMOR-NECROSIS-FACTOR; SEVERE CROHNS-DISEASE; VEDOLIZUMAB INDUCTION THERAPY; REAL-WORLD EXPERIENCE; C-REACTIVE PROTEIN; ANTI-TNF THERAPY; ULCERATIVE-COLITIS; INFLIXIMAB THERAPY; MAINTENANCE THERAPY; GENE-EXPRESSION;

D O I：

10.1016/S2468-1253(18)30265-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Biological therapy has led to marked improvements in treatment of patients with inflammatory bowel disease, and an increasing number of drugs has been approved for treatment. However, only a subgroup of patients responds to therapy, highlighting the need to identify biomarkers for therapeutic response to allow personalised medicine in inflammatory bowel disease. Potential markers of response to biological therapy have been identified; however, studies also suggest that changes in the composition of immune cell infiltrates in response to therapeutic pressure lead to molecular resistance to these drugs. For instance, the cytokine interleukin 23 has been identified as a driver of evasion of apoptosis in response to anti-tumour necrosis factor drugs in patients with Crohn's disease, leading to expansion of apoptosis-resistant T cells and drug resistance. In this Review, we examine the concept of molecular resistance to biological therapy and discuss implications for future therapy.

引用

页码：790 / 802

页数：13

共 100 条

[1] Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease [J].

Adedokun, Omoniyi J. ;

Xu, Zhenhua ;

Gasink, Christopher ;

Jacobstein, Douglas ;

Szapary, Philippe ;

Johanns, Jewel ;

Gao, Long-Long ;

Davis, Hugh M. ;

Hanauer, Stephen B. ;

Feagan, Brian G. ;

Ghosh, Subrata ;

Sandborn, William J. .

GASTROENTEROLOGY, 2018, 154 (06) :1660-1671

[2] Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis [J].

Adedokun, Omoniyi J. ;

Sandborn, William J. ;

Feagan, Brian G. ;

Rutgeerts, Paul ;

Xu, Zhenhua ;

Marano, Colleen W. ;

Johanns, Jewel ;

Zhou, Honghui ;

Davis, Hugh M. ;

Cornillie, Freddy ;

Reinisch, Walter .

GASTROENTEROLOGY, 2014, 147 (06) :1296-+

[3] One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study [J].

Amiot, A. ;

Serrero, M. ;

Peyrin-Biroulet, L. ;

Filippi, J. ;

Pariente, B. ;

Roblin, X. ;

Buisson, A. ;

Stefanescu, C. ;

Trang-Poisson, C. ;

Altwegg, R. ;

Marteau, P. ;

Vaysse, T. ;

Bourrier, A. ;

Nancey, S. ;

Laharie, D. ;

Allez, M. ;

Savoye, G. ;

Moreau, J. ;

Vuitton, L. ;

Viennot, S. ;

Aubourg, A. ;

Pelletier, A. -L. ;

Bouguen, G. ;

Abitbol, V. ;

Gagniere, C. ;

Bouhnik, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) :310-321

[4] Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases [J].

Ananthakrishnan, Ashwin N. ;

Luo, Chengwei ;

Yajnik, Vijay ;

Khalili, Hamed ;

Garber, John J. ;

Stevens, Betsy W. ;

Cleland, Thomas ;

Xavier, Ramnik J. .

CELL HOST & MICROBE, 2017, 21 (05) :603-+

[5] Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis [J].

Arijs, I. ;

Li, K. ;

Toedter, G. ;

Quintens, R. ;

Van Lommel, L. ;

Van Steen, K. ;

Leemans, P. ;

De Hertogh, G. ;

Lemaire, K. ;

Ferrante, M. ;

Schnitzler, F. ;

Thorrez, L. ;

Ma, K. ;

Song, X. -Y R. ;

Marano, C. ;

Van Assche, G. ;

Vermeire, S. ;

Geboes, K. ;

Schuit, F. ;

Baribaud, F. ;

Rutgeerts, P. .

GUT, 2009, 58 (12) :1612-1619

[6] Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC [J].

Arijs, Ingrid ;

De Hertogh, Gert ;

Lemmens, Bart ;

Van Lommel, Leentje ;

de Bruyn, Magali ;

Vanhove, Wiebe ;

Cleynen, Isabelle ;

Machiels, Kathleen ;

Ferrante, Marc ;

Schuit, Frans ;

Van Assche, Gert ;

Rutgeerts, Paul ;

Vermeire, Severine .

GUT, 2018, 67 (01) :43-52

[7] Predictive Value of Epithelial Gene Expression Profiles for Response to Infliximab in Crohn's Disease [J].

Arijs, Ingrid ;

Quintens, Roel ;

Van Lommel, Leentje ;

Van Steen, Kristel ;

De Hertogh, Gert ;

Lemaire, Katleen ;

Schraenen, Anica ;

Perrier, Clementine ;

Van Assche, Gert ;

Vermeire, Severine ;

Geboes, Karel ;

Schuit, Frans ;

Rutgeerts, Paul .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (12) :2090-2098

[8] An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease [J].

Arnott, IDR ;

McNeill, G ;

Satsangi, J .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1451-1457

[9]

Atreya R., 2011, Gastroenterology

[10] In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease [J].

Atreya, Raja ;

Neumann, Helmut ;

Neufert, Clemens ;

Waldner, Maximilian J. ;

Billmeier, Ulrike ;

Zopf, Yurdaguel ;

Willma, Marcus ;

App, Christine ;

Muenster, Tino ;

Kessler, Hermann ;

Maas, Stefanie ;

Gebhardt, Bernd ;

Heimke-Brinck, Ralph ;

Reuter, Eva ;

Doerje, Frank ;

Rau, Tilman T. ;

Uter, Wolfgang ;

Wang, Thomas D. ;

Kiesslich, Ralf ;

Vieth, Michael ;

Hannappel, Ewald ;

Neurath, Markus F. .

NATURE MEDICINE, 2014, 20 (03) :313-318

← 1 2 3 4 5 6 7 8 9 10 →